PinkDx
The Gyne Cancer Company™
Transforming the diagnostic journey in gynecologic cancer
Applying scientific discovery to resolve clinical challenges in gynecologic cancer — giving women and physicians the answers they deserve
Every five minutes in the U.S., another woman is diagnosed with a gynecologic cancer.
Endometrial cancer is the fastest growing gynecologic cancer and is projected to surpass colorectal cancer as the third most common in women by 2030.
More than 90% of women who are diagnosed with endometrial cancer present with abnormal or postmenopausal bleeding.
Yet only about 5% of women evaluated for bleeding will ultimately be diagnosed with endometrial cancer.
Too often, that workup leads to repeat testing, more invasive procedures, added cost, and delayed answers.
